abrdn U.S. Small Cap Equity Fund on Travere Therapeutics, Inc.
Thesis
Travere Therapeutics specialises in treatments for rare kidney and metabolic disorders. Its foundational drug was recently approved for an additional kidney disease, expanding the commercial opportunity. The company also has promising clinical candidates in its pipeline, and the fund believes these opportunities combined with strong commercial execution can support growth.
“We believe the combination of these opportunities with strong commercial execution could support growth.”